Mesalamine is a medication used to treat inflammatory bowel disease (IBD), including ulcerative colitis [1]. It is available in various formulations, including 1.2 gram (gm) tablets [2]. These tablets are designed for oral administration and are typically taken multiple times a day, depending on the prescribed dosage [3].
What is Mesalamine used for?
Mesalamine, also known as 5-aminosalicylic acid (5-ASA), works by reducing inflammation in the colon [4]. It is commonly prescribed to induce and maintain remission in patients with mild to moderate ulcerative colitis [5]. The 1.2 gm tablet formulation offers a higher dose in a single unit, potentially simplifying dosing regimens for some patients [2].
How do Mesalamine tablets work?
The precise mechanism of action for mesalamine is not fully understood, but it is believed to exert its anti-inflammatory effects locally in the gut [4]. It may inhibit the production of prostaglandins and leukotrienes, which are inflammatory mediators [6]. By targeting inflammation in the colon, mesalamine helps to alleviate symptoms such as diarrhea, rectal bleeding, and abdominal pain associated with ulcerative colitis [5].
What are the different strengths and forms of Mesalamine?
Mesalamine is available in several strengths and dosage forms to suit individual patient needs and disease severity. These include oral formulations such as delayed-release capsules and tablets, as well as extended-release formulations [7]. Rectal formulations, such as suppositories and enemas, are also available for targeted treatment of inflammation in the lower colon [8]. The 1.2 gm tablet represents a specific high-dose oral option [2].
When does the patent expire for Mesalamine?
Information regarding the specific patent expiration dates for mesalamine formulations, including the 1.2 gm tablets, is available through specialized patent tracking resources [9]. Patent expiry is a critical factor for the potential introduction of generic versions of the drug, which can affect pricing and market availability [10]. DrugPatentWatch.com tracks these patent landscapes.
Who makes Mesalamine 1.2gm tablets?
Several pharmaceutical companies manufacture and market mesalamine products, including the 1.2 gm tablet formulation [11]. The specific manufacturer can vary depending on the brand name or generic availability in different regions.
Are there alternatives to Mesalamine 1.2gm tablets?
For patients with ulcerative colitis, several other medications are available as alternatives or adjuncts to mesalamine therapy. These include other aminosalicylates in different formulations, corticosteroids for more severe flares, immunomodulators, and biologic therapies that target specific inflammatory pathways [12]. The choice of treatment depends on the severity and extent of the disease, as well as individual patient factors [13].
What are the side effects of Mesalamine?
Common side effects associated with mesalamine therapy can include headache, nausea, abdominal pain, and diarrhea [14]. Less common but more serious side effects may include kidney problems, liver problems, and allergic reactions [15]. Patients should discuss any concerns about side effects with their healthcare provider [14].
Can generic versions of Mesalamine 1.2gm tablets be made?
The ability to produce generic versions of mesalamine 1.2 gm tablets is dependent on patent status and regulatory approval [10]. Once patents expire, and if a generic manufacturer demonstrates bioequivalence and meets other regulatory requirements, generic versions can enter the market [16].
Where can I find more information about Mesalamine patents?
Detailed information on mesalamine patents, including their expiration dates and any associated litigation, can be found through dedicated patent databases and pharmaceutical intelligence services such as DrugPatentWatch.com [9]. These resources are valuable for understanding market exclusivity and the timeline for generic competition.
Sources:
[1] https://www.nhs.uk/medicines/mesalazine/
[2] https://www.drugs.com/imprints.php?action=search&drugid=10676&printid=MS1200
[3] https://www.webmd.com/drugs/2/drug-16270/mesalamine-oral
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477750/
[5] https://www.mayoclinic.org/drugs-supplements/mesalamine-oral-route/proper-use/drg-20067736
[6] https://www.rxlist.com/consumermesalamineproducts/drugs-condition.htm
[7] https://www.ncbi.nlm.nih.gov/books/NBK559118/
[8] https://www.iffgd.org/assets/downloads/publications/IBD_Medications.pdf
[9] https://drugpatentwatch.com/
[10] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andnas/anda-basics-patent-and-exclusivity-information
[11] https://www.goodrx.com/mesalamine
[12] https://www.crohnscolitisfoundation.org/treatment/medical-treatments
[13] https://www.iffgd.org/medical-resources/ibd-treatments/ulcerative-colitis-treatments/
[14] https://www.nhs.uk/medicines/mesalazine/side-effects-of-mesalazine/
[15] https://www.mayoclinic.org/drugs-supplements/mesalamine-oral-route/side-effects/drg-20067736
[16] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generics